JTX 8064
Alternative Names: JTX-8064Latest Information Update: 13 Jul 2024
At a glance
- Originator Jounce Therapeutics
- Developer Concentra Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB2 protein inhibitors; Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Updated efficacy and adverse events data from the phase I/II INNATE trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Nov 2023 Jounce Therapeutics completes the Phase I/II INNATE trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Monotherapy) in USA (IV, Infusion) (NCT04669899)
- 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences